Completed PHASE3 INTERVENTIONAL 1-arm NCT00691145

Study to Evaluate the Efficacy and Safety of 0.1% and 0.03% Tacrolimus Ointment Administered in Adults With Moderate to Severe Atopic Dermatitis

A Long-term, Non-comparative, Multi-centre Study to Evaluate the Efficacy and Safety of 0.1% and 0.03% Tacrolimus (FK506) Ointment Administered in Adults With Moderate to Severe Atopic Dermatitis FG-506-06-IT-01

Sponsor: Astellas Pharma Inc

Conditions Dermatitis, Atopic

Interventions tacrolimus ointment

Updated 7 times since 2017 Last updated: Aug 28, 2014 Started: Oct 31, 2002 Primary completion: Feb 28, 2005 Completion: Feb 28, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00691145, this PHASE3 trial focuses on Dermatitis, Atopic and remains completed. Sponsored by Astellas Pharma Inc, it has been updated 7 times since 2002, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Oct 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Astellas Pharma Inc

Data source: Astellas Pharma Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ancona, Italy , Bari, Italy , Battipaglia, Italy , Benevento, Italy , Bergamo, Italy , Bolzano, Italy , Catania, Italy , Genova, Italy , Mantova, Italy , Merano, Italy and 15 more locations